These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 18978501

  • 1. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
    Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M.
    Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
    [Abstract] [Full Text] [Related]

  • 2. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ, Nurmikko TJ, Young CA.
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [Abstract] [Full Text] [Related]

  • 3. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ, Nurmikko TJ, Friede T, Young CA.
    Neurology; 2005 Sep 27; 65(6):812-9. PubMed ID: 16186518
    [Abstract] [Full Text] [Related]

  • 4. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
    Cannabis-In-Cachexia-Study-GroupDivision of Oncology/Hematology, Department of Internal Medicine, Cantonal Hospital, St Gallen, Switzerland. florian.strasser@kssg.ch, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T.
    J Clin Oncol; 2006 Jul 20; 24(21):3394-400. PubMed ID: 16849753
    [Abstract] [Full Text] [Related]

  • 5. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
    D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH.
    Biol Psychiatry; 2005 Mar 15; 57(6):594-608. PubMed ID: 15780846
    [Abstract] [Full Text] [Related]

  • 6. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial.
    Lappin MS, Lawrie FW, Richards TL, Kramer ED.
    Altern Ther Health Med; 2003 Mar 15; 9(4):38-48. PubMed ID: 12868251
    [Abstract] [Full Text] [Related]

  • 7. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P.
    Expert Rev Neurother; 2011 Apr 15; 11(4 Suppl):15-9. PubMed ID: 21449855
    [Abstract] [Full Text] [Related]

  • 8. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers.
    Kaufmann RM, Kraft B, Frey R, Winkler D, Weiszenbichler S, Bäcker C, Kasper S, Kress HG.
    Pharmacopsychiatry; 2010 Jan 15; 43(1):24-32. PubMed ID: 20178093
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
    Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C.
    J Neurol Sci; 2004 Mar 15; 218(1-2):103-8. PubMed ID: 14759641
    [Abstract] [Full Text] [Related]

  • 10. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients.
    Yozbatiran N, Baskurt F, Baskurt Z, Ozakbas S, Idiman E.
    J Neurol Sci; 2006 Jul 15; 246(1-2):117-22. PubMed ID: 16678208
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
    Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM.
    Pharmacopsychiatry; 2002 Mar 15; 35(2):57-61. PubMed ID: 11951146
    [Abstract] [Full Text] [Related]

  • 12. Memantine induces reversible neurologic impairment in patients with MS.
    Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J.
    Neurology; 2009 May 12; 72(19):1630-3. PubMed ID: 19092106
    [Abstract] [Full Text] [Related]

  • 13. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
    Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M.
    Eur J Pain; 2009 May 12; 13(5):472-7. PubMed ID: 18603457
    [Abstract] [Full Text] [Related]

  • 14. [Sleepiness and fatigue in multiple sclerosis - comparison of different measuring instruments].
    Kotterba S, Eren E, Fangerau T, Malin JP, Sindern E.
    Fortschr Neurol Psychiatr; 2003 Nov 12; 71(11):590-4. PubMed ID: 14608510
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM.
    Hum Psychopharmacol; 2011 Apr 12; 26(3):224-36. PubMed ID: 21671456
    [Abstract] [Full Text] [Related]

  • 16. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
    Svendsen KB, Jensen TS, Bach FW.
    BMJ; 2004 Jul 31; 329(7460):253. PubMed ID: 15258006
    [Abstract] [Full Text] [Related]

  • 17. [Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication].
    Svendsen KB, Jensen TS, Bach FW.
    Ugeskr Laeger; 2005 Jun 20; 167(25-31):2772-4. PubMed ID: 16014264
    [Abstract] [Full Text] [Related]

  • 18. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis.
    Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RH.
    Mult Scler; 2009 Aug 20; 15(8):998-1005. PubMed ID: 19667024
    [Abstract] [Full Text] [Related]

  • 19. Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.
    Kim J, Chung SY, Park S, Park JH, Byun S, Hwang M, Oh DS, Choi H, Kim MY, Bu YC, Doré S, Whang WW, Kim H.
    Pharmacol Biochem Behav; 2008 Oct 20; 90(4):517-24. PubMed ID: 18550156
    [Abstract] [Full Text] [Related]

  • 20. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.
    Neurology; 2009 May 05; 72(18):1555-61. PubMed ID: 19176895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.